Treatment with Volanesorsen (VLN) Reduced Triglycerides and Pancreatitis in Patients with FCS and sHTG vs Placebo: Results of the APPROACH and COMPASS Studies - Sorbonne Université Access content directly
Conference Papers Year : 2018

Treatment with Volanesorsen (VLN) Reduced Triglycerides and Pancreatitis in Patients with FCS and sHTG vs Placebo: Results of the APPROACH and COMPASS Studies

Andres Gelrud
  • Function : Author
Andres Digenio
  • Function : Author
Veronica Alexander
  • Function : Author
Karren Williams
  • Function : Author
Ionna Gouni-Berthold
  • Function : Author
Eric Bruckert
  • Function : Author
Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases
Erik Stroes
  • Function : Author
Richard Geary
  • Function : Author
Steven Hughes
  • Function : Author
Sotirios Tsimikas
  • Function : Author
Daniel Gaudet
  • Function : Author

Domains

Life Sciences [q-bio]

Maryse Guerin  : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-03969825

Submitted on : Thursday, February 2, 2023-2:44:26 PM

Last modification on : Saturday, October 7, 2023-9:36:24 PM

No file

Dates and versions

hal-03969825 , version 1 (02-02-2023)

Identifiers

Cite

Andres Gelrud, Andres Digenio, Veronica Alexander, Karren Williams, Ionna Gouni-Berthold, et al.. Treatment with Volanesorsen (VLN) Reduced Triglycerides and Pancreatitis in Patients with FCS and sHTG vs Placebo: Results of the APPROACH and COMPASS Studies. International Symposium on Atherosclerosis (ISA), Jun 2019, Toronto, Canada. pp.157, ⟨10.1016/j.atherosclerosissup.2018.04.476⟩. ⟨hal-03969825⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

ICAN SORBONNE-UNIVERSITE SU-MEDECINE IHU_ICAN
5 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More